Revolution Medicines, Inc. (RVMD) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
17.61
↑+337% vs avg
5yr avg: 4.03
30Y Low1.8·High9.3
ROE
↓
-58.1%
↑-48% vs avg
5yr avg: -39.1%
30Y Low-83%·High-29%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RVMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Revolution Medicines, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $29.8B | $15.1B | $7.3B | $3.2B | $1.9B | $1.8B | $2.6B | — | — | — |
| Enterprise Value | $29.5B | $14.9B | $6.9B | $2.6B | $1.8B | $1.8B | $2.6B | — | — | — |
| P/E Ratio → | -25.39 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 280.24 | 54.28 | 62.35 | 61.34 | — | — | — |
| P/B Ratio | 17.61 | 9.28 | 3.24 | 1.78 | 2.80 | 3.04 | 5.55 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RVMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 227.71 | 51.54 | 60.93 | 59.68 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
RVMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -58.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | — | — | — | -4207.1% | -730.0% | -639.7% | -257.5% | -108.2% | -200.0% | — |
| Net Profit Margin | — | — | — | -3768.3% | -703.0% | -636.6% | -251.6% | -95.2% | -207.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -29.3% | -34.8% | -38.6% | -34.7% | -34.5% | -38.3% | -82.6% | -687.0% |
| ROA | -46.1% | -46.1% | -26.0% | -30.4% | -32.1% | -28.7% | -27.5% | -24.4% | -45.0% | -206.5% |
| ROIC | -54.3% | -54.3% | -33.6% | -40.5% | -33.7% | -29.3% | -30.8% | -49.8% | -266.8% | — |
| ROCE | -53.0% | -53.0% | -32.0% | -36.5% | -36.2% | -31.4% | -31.7% | -34.1% | -54.7% | -416.2% |
RVMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $384M exceeds total debt of $159M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.06 | 0.05 | 0.09 | 0.11 | 0.07 | — | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.18 | -0.33 | -0.14 | -0.07 | -0.15 | -0.11 | -0.72 | -2.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -48.80 | -48.80 | — | -1607.87 | — | -15667.33 | -1559.11 | -510.57 | -347.66 | -302.22 |
Net cash position: cash ($384M) exceeds total debt ($159M)
RVMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Revolution Medicines, Inc.'s current ratio of 7.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.06x to 7.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.80 | 1.24 |
| Quick Ratio | 7.14 | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 | 9.63 | 3.11 | 2.58 | 1.24 |
| Cash Ratio | 6.97 | 6.97 | 13.97 | 12.88 | 10.40 | 9.56 | 9.34 | 2.85 | 2.28 | 1.19 |
| Asset Turnover | — | — | — | 0.01 | 0.04 | 0.04 | 0.08 | 0.23 | 0.12 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 39.53 | 48.21 | 73.63 | 54.29 | 63.73 | 132.19 | — |
RVMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Revolution Medicines, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $190M | $168M | $113M | $81M | $73M | $67M | $36M | $36M | $36M |
Peer Comparison
Compare RVMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RVMDYou | $30B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 MRSN | $145M | -2.1 | — | — | 100.0% | -181.1% | -505.1% | — | — |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 BDTX | $161M | 7.2 | 12.0 | 5.4 | — | — | 22.9% | 10.7% | 1.2 |
 TNGX | $3B | -27.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 ERAS | $3B | -15.8 | — | — | — | — | -43.7% | -39.2% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Full RVMD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See RVMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RVMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RVMD vs MRSN
Side-by-side business, growth, and profitability comparison vs Mersana Therapeutics, Inc..
Start ComparisonRVMD — Frequently Asked Questions
Quick answers to the most common questions about buying RVMD stock.
What is Revolution Medicines, Inc.'s P/E ratio?
Revolution Medicines, Inc.'s current P/E ratio is -25.4x. This places it at the 50th percentile of its historical range.
What is Revolution Medicines, Inc.'s ROE?
Revolution Medicines, Inc.'s return on equity (ROE) is -58.1%. The historical average is -43.9%.
Is RVMD stock overvalued?
Based on historical data, Revolution Medicines, Inc. is trading at a P/E of -25.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.